Directly Acting Oral Anticoagulants for the Prevention of Stroke in Atrial Fibrillation in England and Wales: Cost-Effectiveness Model and Value of Information Analysis

Objectives. Determine the optimal, licensed, first-line anticoagulant for prevention of ischemic stroke in patients with non-valvular atrial fibrillation (AF) in England and Wales from the UK National Health Service (NHS) perspective and estimate value to decision making of further research. Methods. We developed a cost-effectiveness model to compare warfarin (international normalized ratio target range 2–3) with directly acting (or non–vitamin K antagonist) oral anticoagulants (DOACs) apixaban 5 mg, dabigatran 150 mg, edoxaban 60 mg, and rivaroxaban 20 mg, over 30 years post treatment initiation. In addition to death, the 17-state Markov model included the events stroke, bleed, myocardial infarction, and intracranial hemorrhage. Input parameters were informed by systematic literature reviews and network meta-analysis. Expected value of perfect information (EVPI) and expected value of partial perfect information (EVPPI) were estimated to provide an upper bound on value of further research. Results. At willingness-to-pay threshold £20,000, all DOACs have positive expected incremental net benefit compared to warfarin, suggesting they are likely cost-effective. Apixaban has highest expected incremental net benefit (£7533), followed by dabigatran (£6365), rivaroxaban (£5279), and edoxaban (£5212). There was considerable uncertainty as to the optimal DOAC, with the probability apixaban has highest net benefit only 60%. Total estimated population EVPI was £17.94 million (17.85 million, 18.03 million), with relative effect between apixaban versus dabigatran making the largest contribution with EVPPI of £7.95 million (7.66 million, 8.24 million). Conclusions. At willingness-to-pay threshold £20,000, all DOACs have higher expected net benefit than warfarin but there is considerable uncertainty between the DOACs. Apixaban had the highest expected net benefit and greatest probability of having highest net benefit, but there is considerable uncertainty between DOACs. A head-to-head apixaban versus dabigatran trial may be of value.

[1]  P. Scarborough,et al.  Estimating comparable English healthcare costs for multiple diseases and unrelated future costs for use in health and public health economic modelling , 2018, PloS one.

[2]  Fernando Alarid-Escudero,et al.  A Gaussian Approximation Approach for Value of Information Analysis , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  Gianluca Baio,et al.  Efficient Monte Carlo Estimation of the Expected Value of Sample Information Using Moment Matching , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

[4]  Deborah M Caldwell,et al.  Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis , 2017, BMJ.

[5]  J. Sterne,et al.  Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. , 2017, Health technology assessment.

[6]  Chieh-Yu Liu,et al.  Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan , 2017, Clinical Drug Investigation.

[7]  B. Martin,et al.  Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients , 2016, Stroke.

[8]  A. Ramos-Esquivel Monitoring anticoagulant therapy with new oral agents. , 2015, World journal of methodology.

[9]  Nicky J Welton,et al.  Value of Information , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  Á. Avezum,et al.  Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. , 2015, European heart journal.

[11]  F Gueyffier,et al.  Multivariate meta-analysis using individual participant data , 2014 .

[12]  V. Thijs,et al.  Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin , 2015, Clinical Drug Investigation.

[13]  S. Sorensen,et al.  Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. , 2014, Clinical therapeutics.

[14]  A. de Boer,et al.  Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings , 2014, American Journal of Cardiovascular Drugs.

[15]  I. Durand-zaleski,et al.  Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin , 2014, Journal of medical economics.

[16]  G. Lip,et al.  Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. , 2014, Clinical therapeutics.

[17]  Ramon Luengo-Fernandez,et al.  Population-Based Study of Acute- and Long-Term Care Costs after Stroke in Patients with AF , 2013, International journal of stroke : official journal of the International Stroke Society.

[18]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 5 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[19]  D. Malone,et al.  Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation , 2013, Stroke.

[20]  Å. Reikvam,et al.  Efficacy and cost-effectiveness of new oral anticoagulants compared to warfarin for the prevention of stroke in patients with atrial fibrillation , 2013 .

[21]  H. Kamel,et al.  Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation , 2012, Neurology.

[22]  J. Kluger,et al.  Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. , 2012, The American journal of cardiology.

[23]  Mårten Rosenqvist,et al.  Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. , 2012, European heart journal.

[24]  Paul Robinson,et al.  Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation , 2012, Heart.

[25]  Adrian V. Hernández,et al.  Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. , 2012, Archives of internal medicine.

[26]  S. Yusuf,et al.  Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial , 2012, Circulation.

[27]  A. Capucci,et al.  Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.

[28]  B. Gage,et al.  Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation , 2010, Circulation.

[29]  Alan Brennan,et al.  Simulation sample sizes for Monte Carlo partial EVPI calculations. , 2010, Journal of health economics.

[30]  H. Crijns,et al.  Factors determining utility measured with the EQ-5D in patients with atrial fibrillation , 2010, Quality of Life Research.

[31]  David Garcia,et al.  The new oral anticoagulants. , 2010, Blood.

[32]  D. Singer,et al.  Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. , 2009, American heart journal.

[33]  T. Olsen,et al.  Reduced Poststroke Mortality in Patients With Stroke and Atrial Fibrillation Treated With Anticoagulants: Results From a Danish Quality-Control Registry of 22 179 Patients With Ischemic Stroke , 2007, Stroke.

[34]  Uwe Siebert,et al.  Long-Term Outcome After Stroke Evaluating Health-Related Quality of Life Using Utility Measurement , 2006 .

[35]  A. Hofman,et al.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. , 2006, European heart journal.

[36]  Uwe Siebert,et al.  Long-Term Outcome After Stroke: Evaluating Health-Related Quality of Life Using Utility Measurements , 2006, Stroke.

[37]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .

[38]  V. Santinelli,et al.  Prevention of Atrial Fibrillation: , 2004, Journal of cardiovascular electrophysiology.

[39]  M. Pirmohamed,et al.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.

[40]  A E Ades,et al.  Expected Value of Sample Information Calculations in Medical Decision Modeling , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[41]  S. Walters,et al.  Continuing inequality: gender and social class influences on self perceived health after a heart attack , 2003, Journal of epidemiology and community health.

[42]  R. Sy Evaluating health related quality of life using utility measurements for chronic hepatitis C , 2001 .

[43]  M Eccles,et al.  How patients with atrial fibrillation value different health outcomes: a standard gamble study. , 2001, Journal of health services research & policy.

[44]  Paul Kind,et al.  UK population norms for EQ-5D , 1999 .

[45]  O. Benavente,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.

[46]  P A Wolf,et al.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. , 1998, The American journal of cardiology.

[47]  A. Mcguire,et al.  Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. , 1998, Stroke.

[48]  Gordon B. Hazen,et al.  Sensitivity Analysis and the Expected Value of Perfect Information , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[49]  Leslie Lenert,et al.  Jamia Original Investigations Automated Computer Interviews to Elicit Utilities: Potential Applications in the Treatment of Deep Venous Thrombosis , 2022 .

[50]  Peter Mittler,et al.  State of the nation , 1995 .

[51]  Howard Raiffa,et al.  Applied Statistical Decision Theory. , 1961 .